mBio (Oct 2021)
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
- Denise Haslwanter,
- M. Eugenia Dieterle,
- Anna Z. Wec,
- Cecilia M. O’Brien,
- Mrunal Sakharkar,
- Catalina Florez,
- Karen Tong,
- C. Garrett Rappazzo,
- Gorka Lasso,
- Olivia Vergnolle,
- Ariel S. Wirchnianski,
- Robert H. Bortz,
- Ethan Laudermilch,
- J. Maximilian Fels,
- Amanda Mengotto,
- Ryan J. Malonis,
- George I. Georgiev,
- Jose A. Quiroz,
- Daniel Wrapp,
- Nianshuang Wang,
- Kathryn E. Dye,
- Jason Barnhill,
- John M. Dye,
- Jason S. McLellan,
- Johanna P. Daily,
- Jonathan R. Lai,
- Andrew S. Herbert,
- Laura M. Walker,
- Kartik Chandran,
- Rohit K. Jangra
Affiliations
- Denise Haslwanter
- ORCiD
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- M. Eugenia Dieterle
- ORCiD
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Anna Z. Wec
- Adimab LLC, Lebanon, New Hampshire, USA
- Cecilia M. O’Brien
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
- Mrunal Sakharkar
- Adimab LLC, Lebanon, New Hampshire, USA
- Catalina Florez
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Karen Tong
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- C. Garrett Rappazzo
- Adimab LLC, Lebanon, New Hampshire, USA
- Gorka Lasso
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Olivia Vergnolle
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- Ariel S. Wirchnianski
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Robert H. Bortz
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Ethan Laudermilch
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- J. Maximilian Fels
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Amanda Mengotto
- Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA
- Ryan J. Malonis
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- George I. Georgiev
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- Jose A. Quiroz
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- Daniel Wrapp
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA
- Nianshuang Wang
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA
- Kathryn E. Dye
- Department of Science, Mount St. Mary’s University, Emmitsburg, Maryland, USA
- Jason Barnhill
- Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, New York, USA
- John M. Dye
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
- Jason S. McLellan
- ORCiD
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA
- Johanna P. Daily
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Jonathan R. Lai
- Department of Biochemistry, Albert Einstein College of Medicine, New York, New York, USA
- Andrew S. Herbert
- U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
- Laura M. Walker
- Adimab LLC, Lebanon, New Hampshire, USA
- Kartik Chandran
- ORCiD
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- Rohit K. Jangra
- ORCiD
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA
- DOI
- https://doi.org/10.1128/mBio.02473-21
- Journal volume & issue
-
Vol. 12,
no. 5
Abstract
The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.
